 Rifamycin antibacterial agents, which are first-line treatments for tuberculosis, and lipiarmycin also target RNAP, but target different sites in RNAP.Myxopyronins do not have cross-resistance with rifamycins and lipiarmycin.Myxopyronins may be useful to address the growing problem of drug resistance in tuberculosis.